Long-term peritoneal dialysis (PD) leads to histological changes in the peritoneal membrane.
Introduction
Peritoneal dialysis (PD) is a beneficial therapy for end-stage renal disease. However, longterm PD therapy leads to histopathological changes in the peritoneum, such as peritoneal fibrosis and vasculopathy [1, 2] . Although the mechanisms underlying these structural changes have not been fully elucidated, the angiogenesis and inflammation caused by the glucose degradation products (GDPs) in PD fluid play crucial roles [3, 4] . Some GDPs, such as methylglyoxal (MGO), promote generation of advanced glycation end products (AGEs) [5] [6] [7] . Recent studies have revealed that peritoneal deposition of AGEs increases with the duration of PD, and may correlate with the development of peritoneal fibrosis [4, 6, 8] .
Growing evidence indicates that AGEs evoke angiogenesis through stimulating vascular endothelial growth factor (VEGF), and also induce proinflammatory cytokines [4, 9] . The interaction of AGEs with the receptor for AGEs (RAGE) results in peritoneal damage in diabetic and uremic rats [10] [11] [12] , and causes upregulation of the transcription factor, nuclear factor-B (NF-B) [9, 12, 13] . NF-κB plays a key role in regulating target genes, such as VEGF, monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-1, and IL-6 [9] .
One of the most common GDPs found in PD fluid is MGO, which enhances the formation of AGEs [7] . Previous investigations of rat MGO-induced peritoneal fibrosis have revealed 8 3,3'-diaminobenzidine-4HCl (DAB) and ethylenediaminetetraacetic acid (EDTA) were purchased from Dojin Chemical (Kumamoto, Japan). Tris-HCl, bovine serum albumin (BSA), yeast transfer RNA, salmon testis DNA, normal sheep immunoglobulin G (IgG), and Brij 35 were purchased from Sigma Chemical (St. Louis, MO, USA). All other reagents were purchased from Wako Pure Chemicals (Osaka, Japan).
Antibodies
The following first antibodies were used for immunohistochemistry: (1) mouse anticarboxy methyllysine (CML) (one of AGEs derived from MGO) antibody, diluted 1/50 (KH011; Dojin Chemical); (2) rabbit anti-RAGE antibody, diluted 1/800 (AB5484; Millipore, CA, USA); (3) rabbit anti-type III collagen antibody, diluted 1/400 (LB-1393; LSL Co., Tokyo, Japan); (4) mouse anti--smooth muscle actin (-SMA) antibody, diluted 1/100 (A2547; Sigma), used as a marker of myofibroblasts; (5) rabbit anti-transforming growth factor- (TGF- antibody, diluted 1/100 (sc-146; Santa Cruz, CA, USA); (6) mouse anti-8hydroxydeoxyguanosine (8-OHdG) antibody, diluted 1/100 (MOG-100P; Japan Institute for the Control of Aging, Tokyo, Japan), used as a marker of oxidative stress; (7) rat anti-mouse CD31/PECAM-1 antibody, diluted 1/50 (sc-1506; Santa Cruz), used as a marker of endothelial cells; (8) rabbit anti-VEGF antibody, diluted 1/100 (sc-152; Santa Cruz); (9) rat anti-F4/80 antibody, diluted 1/50 (MCA497; Serotec, Oxford, UK), used as a marker of mouse macrophages; (10) goat anti-mouse MCP-1 antibody, diluted 1/100 (sc-1784; Santa Cruz); and (11) sheep anti-digoxigenin (DIG) horseradish peroxidase (HRP)-conjugated sheep antibody (11207733910; Roche, Mannheim, Germany).
The following antibodies were used as second or third antibodies: (1) HRP-conjugated swine anti-rabbit IgG antibody (P0399; Dako, Glostrup, Denmark); (2) The peroxidaseantiperoxidase reaction (PAP, Z0113; Dako); (3) HRP-conjugated rabbit anti-rat IgG antibody (Z0147; Dako); (4) HRP-conjugated goat anti-mouse IgG antibody (P0447; Dako).
Administration of PD fluid and EGCG
Mice were divided into 4 groups: (1) PD fluid + saline group (n = 6), defined as the control ) intraperitoneally for 15 days, 5 consecutive days per week as described previously [7] . Mice also received saline or 50 mg/kg EGCG in saline subcutaneously for 21 days daily. The dose and interval for MGO injection were selected based on pilot studies.
Mice were sacrificed at day 22. The peritoneal tissues were dissected out and fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) (pH 7.4).
Histological analysis and immunohistochemistry
For histrological examination, 4-m-thick paraffin-embedded tissues were stained using the Masson-trichrome method.
An indirect immunohistochemical technique was used for CML, type III collagen, -SMA, 8-OHdG, and F4/80. The indirect staining was performed as described previously [15, 23] .
In brief, deparaffinized tissue sections were incubated for 30 min with a blocking buffer containing 5% normal goat serum, 5% fetal calf serum, 5% BSA, and 20% normal swine serum in PBS. The sections were then reacted with the primary antibodies, and diluted in the same blocking buffer. Following reaction with anti-type III collagen antibody for 1 h at room temperature, sections were reacted with HRP-conjugated swine anti-rabbit immunoglobulin antibody diluted 1/50, for 30 min at room temperature. The peroxidase-antiperoxidase reaction diluted 1/100 was used. For F4/80, sections were reacted with HRP-conjugated rabbit anti-rat immunoglobulin antibody and HRP-conjugated swine anti-rabbit immunoglobulin antibody, following reaction with anti-F4/80 antibody for 1 h at room temperature. For CML, -SMA, and 8-OHdG, sections were reacted with primary antibodies overnight at room temperature, and HRP-conjugated goat anti-mouse immunoglobulin antibody diluted 1/50, for 1 h at room temperature.
For RAGE, TGF- CD31, VEGF, and MCP-1, tissues were stained by an avidin-biotin complex technique using a Vectastain Elite ABC kit (Vector Laboratories, CA, USA), following reaction with the primary antibody as described previously [15, 23] . In brief, all primary antibodies except for MCP-1 were reacted for 1 h at room temperature. For MCP-1, the primary antibody was reacted overnight at 4°C. Reaction products were visualized by treating sections with 100 L of 30% hydrogen peroxide and 50 mg of DAB. Finally, the sections were counterstained with methyl green and mounted.
Southwestern histochemistry for NF-B
The following single-strand (ss)-oligo-DNAs were synthesized with the specific consensus sequence for the NF-B binding site (5′-GATCGAGGGGGACTTTCCCTAGC-3′ and 5′-GCTAGGGAAAGTCCCCCTCGATC-3′) [24] . Double-strand (ds)-oligo-DNA was 3′-12 labeled with DIG. The synthesized ss-oligo-DNAs were purchased from BEX (Tokyo, Japan).
For annealing of complementary ss-oligo-DNAs to ds-oligo-DNA, the ss-oligo-DNAs were dissolved in 10 mmol/L of Tris-HCl buffer (pH 7.4), denatured for 10 min at 100°C, and gradually cooled to room temperature.
Southwestern histochemistry was performed as described previously [25] [26] [27] . In brief, deparaffinized sections (4-m-thick) were treated in a microwave oven with citrate buffer (pH 6.0) at 95°C for 15 min. The sections were then washed in PBS and immersed in a preincubation buffer containing 5% nonfat milk dissolved in 10 mmol/L of Tris-HCl (pH 7.4) with 300 mmol/L of NaCl and 1 mmol/L of EDTA for 1 h. Next, the sections were incubated overnight with the probe dissolved in the pre-incubation buffer at a concentration of 1 g/mL.
The sections were then washed twice with pre-incubation buffer, and 4 times with 0.075% Brij in PBS. Then the sections were incubated in a blocking buffer containing 5% BSA, 500 g/mL of normal sheep IgG, 100 g/mL of yeast transfer RNA, and 100 g/mL of salmon sperm DNA in PBS for 1 h. To visualize hybridized DNA-oligo probes, the sections were immunohistochemically stained with anti-DIG HRP-conjugated sheep antibody, diluted 1/100 in blocking buffer, for 2 h. After 4 washes with 0.075% Brij in PBS, we performed a color reaction with 100 mmol/L of phosphate buffer (pH 7.6), containing 50 mg of DAB and 33 L 13 of 30% hydrogen peroxide. To enhance the reaction, we added 2 mL of 0.5% (v/v) nickel ammonium sulfate solution and 2.5 mL of 0.5% (v/v) cobalt chloride solution. To evaluate the specificity of the probe for NF-B, we also used a mutated probe (5′-GATCGAGGAAGACTTTCCCTAGC-3′ and 5′-GCTAGGGAAAGTCTTCCTCGATC-3′) [24] . Moreover, we hybridized some sections with the probe in the presence of an excess amount of non-labeled homologous ds-oligo-DNA, as described previously [26, 27] .
Morphometric analysis
To assess the thickening of the submesothelial compact zone, we used image analysis software (Lumina Vision Ver. 2.04; Mitani Corp., Fukui, Japan) following Masson-trichrome staining. We measured the thickness of the submesothelial compact zone at 5 randomly selected positions in each tissue at ×200 magnification, and averaged the results.
In each sample, we counted the numbers of RAGE-expressing cells, -SMA-expressing cells, TGF--expressing cells, 8-OHdG-expressing cells, CD31-positive vessels, VEGFexpressing cells F4/80-positive macrophages and MCP-1-expressing cells in 5 fields at ×200 magnification. The results for each tissue were averaged. For CML and type III collagen, we selected 5 areas in each tissue and performed semi-quantitative estimation of the intensity of 14 each protein with Lumina Vision.
Finally, we selected 5 areas in each tissue and evaluated NF-B-activated cells with Lumina Vision.
Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM). Differences among groups were examined for statistical significance using repeated measures analysis of variance (ANOVA) (Bonferroni/Dunn test). A p value <0.05 denotes a statistically significant difference. All statistical analyses were performed with Stat View version 5.0 software (SAS Institute Inc., NC, USA).
RESULTS

Morphological examination following Masson-trichrome staining
In the normal and control mice, the peritoneal tissue consisted of a peritoneal mesothelial monolayer and sparse connective tissues below this layer ( Fig. 1A and B ). Compared to the control group, the peritoneal tissue of the MGO group showed significant thickening of the submesothelial compact zone and the presence of numerous cells ( Fig. 1C and F). The thickness of the submesothelial compact zone in the EGCG group was significantly lower than that of the MGO group ( Fig. 1D and F) . To assess the toxicity of EGCG, we analyzed the PD fluid + EGCG group. Repeated injections of EGCG had no significant effect on the peritoneum ( Fig. 1E and F).
Accumulation of CML and expression of RAGE
We observed very little CML deposition in the peritoneal tissues of the control group ( Fig.   2A and D). The MGO group showed intense staining of CML in the peritoneum ( Fig. 2B and D), whereas the EGCG group showed reduced intensity of CML staining ( Fig. 2C and D) .
The number of RAGE-expressing cells was significantly higher in the MGO group than in the control group ( Fig. 2E , F, and H), but significantly lower in the EGCG group than in the MGO group ( Fig. 2F , G, and H).
Expression of type III collagen, -SMA, and TGF-
In the control group, type III collagen expression in the submesothelial compact zone was equivalent to that of normal mice (Fig. 3A) . In the MGO group, type III collagen was diffusely expressed, and the positive areas were significantly larger than those of the control group ( Fig. 3B and D) . EGCG administration significantly reduced the expression of type III collagen ( Fig. 3C and D) .
Previous studies have shown that peritoneal myofibroblasts and mesothelial cells produce collagen, and that collagen deposition is mainly due to myofibroblasts [28, 29] . Thus, we investigated -SMA-expressing cells as a marker of myofibroblasts. In the MGO group, we observed the expression of -SMA in vascular smooth muscle cells, and also numerous -SMA-expressing myofibroblasts ( Fig. 4A and Table) . On the contrary, the EGCG group contained markedly fewer -SMA-positive myofibroblasts (Fig. 4B and Table) . We also investigated fibroblast specific marker-1 (FSP-1) as an immunohistochemical marker of fibroblasts and myofibroblasts. The number of FSP-1 positive cells was greater than that of -SMA positive cells in the submesothelial compact zone (data not shown). This suggested that not only myofibroblasts but also fibroblasts were present in the peritoneal tissue.
-SMA-positive myofibroblasts are derived from resident fibroblasts, and fibroblastmyofibroblast differentiation is mainly mediated by TGF- [30] . Therefore, we also evaluated the levels of TGF--expressing cells. In the MGO group, the number of TGF-expressing cells was higher than that of the control group ( Fig. 4C and Table) . However, the EGCG group contained fewer TGF--expressing cells ( Fig. 4D and Table) .
Expression of 8-OHdG
EGCG is known to possess an anti-oxidative effect [17] . Therefore, we evaluated 8-OHdG as a marker of oxidative stress. We found that 8-OHdG-expressing cells were mainly located in the submesothelial compact zone. However, the numbers of 8-OHdG-expressing cells differed significantly between the groups. In the control group, the number of 8-OHdGexpressing cells was slightly higher than that of normal mice (data not shown). In the MGO group, the number of 8-OHdG-expressing cells was higher than that of the control group ( Fig.   4E and Table) . Meanwhile, the EGCG group contained fewer 8-OHdG-expressing cells ( Fig.   4F and Table) .
Expression of CD31 and VEGF
We investigated angiogenesis in peritoneal fibrosis, and quantified the number of CD31positive blood vessels. In the MGO group, the number of blood vessels was markedly higher than in the control group (Fig. 5A and Table) . However, the EGCG group contained fewer blood vessels ( Fig. 5B and Table) .
VEGF is a potent stimulator of angiogenesis. Therefore, we evaluated VEGF in the peritoneal tissue. In the MGO group, the number of VEGF-expressing cells was markedly higher than in the control group ( Fig. 5C and Table) . However, the EGCG group contained fewer VEGF-expressing cells in the submesothelial zone ( Fig. 5D and Table) .
Expression of F4/80 and MCP-1
To investigate inflammation, we stained sections with anti-F4/80 antibody, as a marker of macrophages. In the MGO group, we observed numerous macrophages in the thickened peritoneal tissues ( Fig. 5E and Table) . However, the EGCG group contained significantly fewer macrophages than did the MGO group (Fig. 5F ).
We also investigated the levels of MCP-1-expressing cells, which exert an important effect on macrophage infiltration. In the MGO group, the number of MCP-1-expressing cells was 19 significantly higher than that in the control group ( Fig. 5G and Table) . Compared to the MGO group, the EGCG group contained significantly fewer MCP-1-expressing cells ( Fig.   5H and Table) .
Southwestern histochemistry for NF-B
EGCG has been shown to suppress NF-B signaling [31, 32] . Therefore, we investigated the expression of activated NF-B in our model. Southwestern histochemistry is used to detect activated transcription regulatory factors that bind to specific sequences of DNA [25, 26] .
The number of NF-B-activated cells in the submesothelial compact zone of the MGO group was significantly higher than that of the control group (Fig. 6A, B, and D) . Compared to the MGO group, the EGCG group contained significantly fewer NF-B-activated cells ( Figure 6C and D) . To evaluate the specificity, we performed the same procedure using a mutated probe. In this case, only a weak nuclear staining for NF-B was detected (data not shown). When an excess amount of non-labeled probe was added to the standard mixture containing DIG-labeled probe, absent or weak nuclear staining for NF-B was detected (data not shown). 20 
Discussion
In the present study, MGO administration markedly increased the thickness of the submesothelial compact zone, the number of blood vessels and macrophages, and the intensity of immunohistochemical staining for CML in the mouse peritoneum. Moreover, mice died from colon adhesion and we observed the formation of abdominal cocoons (data not shown). All of these changes, reflecting the features of human peritoneal fibrosis, were significantly suppressed in the EGCG group. Our results strongly indicate that EGCG ameliorates peritoneal fibrosis.
The underlying mechanisms of encapsulating peritoneal sclerosis (EPS) in humans are not fully understood. With respect to vasculopathy in the MGO-induced peritoneal fibrosis model, the number of vessels increased in the MGO group, which is similar to human peritoneal fibrosis [1] . However, it was difficult to evaluate morphological changes in the vessels because of the small size of the vessels in mice. In the perineum of patients on longterm peritoneal dialysis, vasculopathy tends to occur in post-capillary venules or capillaries and is marked by stenosis or obstruction of the vascular lumen caused by thickening and hyalinization of the vessels [1, 33] .
Although structural changes could not be evaluated in detail, we found no intraluminal However, peritoneal fibrosis is essential to the development of EPS [4] , and therefore, the prevention of peritoneal fibrosis is important to avoid EPS. Although chlorhexidine gluconate -induced peritoneal fibrosis is a well-established animal model, its principal mechanism is chemical irritation of mesothelial cells. By contrast, GDPs are thought to induce peritoneal fibrosis in humans, and therefore, MGO-induced peritoneal fibrosis more closely resembles human peritoneal fibrosis [34] . Several researchers have used a rat MGOinduced peritoneal fibrosis model [7, 14, 34] . However, to our knowledge, this is the first study to use a mouse MGO-induced peritoneal fibrosis model. The rat MGO models are limited by lack of specificity, and transient efficacy of pharmacologic agents and expression protocols. Genetically modified mice could provide an attractive alternative to such models.
The concentrations of MGO used in the rat MGO-induced peritoneal fibrosis model [7, 14, 34] were <20 mM. However, in mice, we were unable to induce sufficient peritoneal thickness using 20 mM MGO. This may reflect a species-dependent difference. Thus, we adopted the experimental protocol described in the Materials and methods.
Accumulated evidence indicates that GDPs can react with protein and generate AGEs, which are known to be important precursors of peritoneal fibrosis. The extent of AGEs and RAGE expression in the peritoneal submesothelial compact zone has been shown to correlate with the duration of PD therapy [8, 13] . In general, RAGE is expressed in a variety of cell types, including endothelial cells, vascular smooth muscle cells, macrophages, mesangial cells, and neurons [35] . RAGE expression is low during homeostasis, but strikingly enhanced in conditions such as diabetes, uremia, and inflammation [10] . The AGEs-RAGE interaction activates numerous signaling cascades, including the MAPK cascade and NF-B signaling, and plays an important role in peritoneal fibrosis. The interaction also mediates the generation of reactive oxygen species (ROS), which in turn activate TGF--Smad signaling [12, 16] . In the present study, we observed an increase in TGF--positive cells, and also in 8-OHdG-positive cells, following the administration of MGO. Our results suggest that the generation of ROS may increase the activity of TGF-.
We have demonstrated for the first time that EGCG attenuates MGO-induced peritoneal fibrosis. Previous reports have revealed that EGCG inhibits the nuclear translocation of NF- 23 B [36] , the phosphorylating activity of inhibitory B kinase-β [37] , and the phosphorylation of the MAPK cascade [38] , which is upstream of NF-B. Suppression of NF-B activation has been linked with anti-inflammatory and anti-angiogenesis activity. Thus, we postulated that EGCG exerts its inhibitory effects on MCP-1 and VEGF expression, at least in part, through the suppression of NF-B activity. We analyzed activated NF-B expression using Southwestern histochemistry and observed that the levels of NF-B activation correlated with the progression of peritoneal thickness, and also with the expression levels of MCP-1 and VEGF.
EGCG should be administrated intraperitoneally, intravenously, or subcutaneously, while considering the involvement of liver metabolism and glucuronidation of EGCG following oral administration [39, 40] . For intraperitoneal injection, direct interaction between EGCG and MGO should be considered. In addition, repeated intravenous injections were technically difficult and created the potential for procedural artifacts in our study. According to the literature, the bioavailability of subcutaneously injected EGCG was superior to that of the orally administered drug [41] . Thus, we adopted the subcutaneous injection of EGCG as the route of administration.
We considered the possibility that EGCG pharmacologically inhibits MGO since Wu et al. 24 showed that EGCG prevented production of AGEs in vitro [42] . Therefore, we adopted different EGCG and MGO administration methods to minimize the impact of EGCG on MGO-derived AGE production in our study. To clarify the precise mechanisms of EGCG prevention of MGO-induced peritoneal fibrosis, further investigations will be needed.
The amount of EGCG used in our study was almost 10 times higher than that contained in daily drinking tea [43] . A previous report demonstrated that daily administration of 200 mg/kg EGCG did not induce toxicity in rats during short-term observation [44] . In our pathophysiological investigation, there was no difference in the liver and kidney tissues of the PD fluid + EGCG and control groups. Moreover, there was no difference in serum creatinine levels at 3 weeks (data not shown). However, according to the reference, long-term and highdose EGCG administration can induce liver toxicity [45] . The appropriate quantity and method of administration for humans, and the long-term toxicity should be examined prior to clinical application.
In conclusion, we have shown for the first time that EGCG inhibits the progression of Table: Results of immunohistochemistry for TGF-β, α-SMA, 8-OHdG, CD31, VEGF, F4/80, and MCP-1
